BRAF and colorectal carcinoma: Furthermore, the PARPi talazoparib synergized with radiotherapy in CRC cells with both wild-type BRAF (i.e., DLD-1) and mutant BRAF (i.e., RKO), while olaparib had lower synergistic effects [67].